|
Baclofen
(bak' loe fen).
Butanoic acid, 4-amino-3-(4-chlorophenyl)-. » Baclofen contains not less than 99.0 percent and not more than 101.0 percent of C10H12ClNO2, calculated on the anhydrous basis.
Packaging and storage
Preserve in tight containers.
Water, Method I
Residue on ignition
Heavy metals, Method II
Related compounds
[Caution: Avoid contact with o-tolidine when performing this test, and conduct the test in a well-ventilated hood.
]
Detection reagent
Dissolve 200 mg of o-tolidine in 2.0 mL of glacial acetic acid with the aid of a hot water bath. Dilute with water to 100.0 mL, and filter. Mix one volume of this solution with an equal volume of potassium iodide solution (0.83 in 100).
Diluting solution
Prepare a mixture of alcohol and glacial acetic acid (4:1).
Standard preparations
Dissolve USP Baclofen RS in Diluting solution to obtain a Standard stock solution having a known concentration of 0.1 mg per mL. Dilute portions of this Standard stock solution quantitatively with Diluting solution to obtain solutions having concentrations of 0.05 mg per mL (Standard preparation A) and 0.03 mg per mL (Standard preparation B), respectively.
Identification preparation
Dissolve USP Baclofen Related Compound A RS in Diluting solution to obtain a solution having a known concentration of 0.1 mg per mL.
Test preparation
Prepare a solution in Diluting solution containing 10.0 mg of Baclofen per mL.
Procedure
Apply separately 10 µL of the Test preparation, Identification preparation, Standard preparation A, and Standard preparation B to a suitable thin-layer chromatographic plate (see Chromatography
Assay
Dissolve about 200 mg of Baclofen, accurately weighed, in a suitable volume of glacial acetic acid, sufficient to immerse the electrodes. Titrate with 0.1 N perchloric acid VS, determining the endpoint potentiometrically, using a glass electrode and a calomel electrode containing a saturated solution of lithium chloride in glacial acetic acid (see Titrimetry
Auxiliary Information
Please check for your question in the FAQs before contacting USP.
USP35NF30 Page 2300
Pharmacopeial Forum: Volume No. 33(2) Page 211
|